Rylan H.

Rylan H. is an accomplished regulatory affairs executive with extensive experience in the pharmaceutical industry. Currently serving as the Executive Director of Regulatory Affairs for Inflammation and Rare Disease at Amgen since August 2025, Rylan has demonstrated leadership in managing regulatory strategies and processes. Prior roles include Executive Director of Regulatory Strategy at Neurocrine Biosciences, where Rylan was the Global Regulatory Lead for INGREZZA and oversaw key phase 3 programs. Rylan also held positions as Senior Director of Regulatory Affairs at Intercept Pharmaceuticals and Business Process Owner for Regulatory Intelligence at Amgen, contributing to the development of regulatory strategies and policies across various therapeutic areas. An experienced former analyst at the FDA, Rylan has robust expertise in regulatory compliance and public policy related to pharmaceuticals, supplemented by a Pharm.D. from the University of Southern California and a B.S. in Biology from California State University-San Bernardino.